BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5-Reference-Cited by-同舟云学术

BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5

Published:2022-12 Issue:12 Volume:22 Page:1663-1665
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Tartof Sara Y,Slezak Jeff M,Puzniak Laura,Hong Vennis,Frankland Timothy B,Ackerson Bradley K,Takhar Harpreet,Ogun Oluwaseye A,Simmons Sarah,Zamparo Joann M,Jodar Luis,McLaughlin John M

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference4 articles.

1. Emergence of SARS-CoV-2 omicron lineages BA.4 and BA.5 in South Africa;Tegally;Nat Med,2022

2. Neutralization of the SARS-CoV-2 omicron BA.4/5 and BA.2.12.1 subvariants;Qu;N Engl J Med,2022

3. SARS-CoV-2 sequences by Variant, Mar 1, 2021,2022

4. BNT162b2 effectiveness and durability against BA.1 and BA.2 hospital and emergency department admissions in a large US health system: a test-negative design;Tartof;SSRN,2022

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modeling the potential public health impact of different vaccination strategies with an adapted vaccine in South Africa;Expert Review of Vaccines;2024-08-28

2. Estimated Effectiveness of the BNT162b2 XBB Vaccine Against COVID-19;JAMA Internal Medicine;2024-08-01

3. The impact of the COVID-19 vaccination programme on symptomatic and severe SARS-CoV-2 infection during a period of Omicron variant dominance in Ireland, December 2021 to March 2023;Eurosurveillance;2024-07-11

4. Effectiveness of BNT162b2 XBB Vaccine Against XBB and JN.1 Sublineages;Open Forum Infectious Diseases;2024-06-28

5. Effectiveness of BNT162b2 Vaccine for Preventing COVID-19-Related Hospitalizations: A Test-Negative Case–Control Study;Vaccines;2024-06-13